Barclays Lowers Moderna (NASDAQ:MRNA) Price Target to $125.00

Moderna (NASDAQ:MRNA) had its price target decreased by Barclays from $155.00 to $125.00 in a research note issued to investors on Monday morning, Benzinga reports. Barclays currently has an overweight rating on the stock.

Several other equities research analysts have also commented on the stock. Bank of America decreased their target price on shares of Moderna from $130.00 to $110.00 and set a neutral rating on the stock in a research report on Friday, September 13th. TD Cowen lowered their target price on shares of Moderna from $70.00 to $60.00 and set a hold rating on the stock in a research report on Friday, September 13th. JPMorgan Chase & Co. downgraded shares of Moderna from a neutral rating to an underweight rating and reduced their price target for the company from $88.00 to $70.00 in a research report on Friday, September 13th. HSBC upgraded Moderna from a reduce rating to a hold rating and set a $82.00 price target on the stock in a report on Wednesday, August 28th. Finally, Royal Bank of Canada reduced their price objective on Moderna from $90.00 to $75.00 and set a sector perform rating for the company in a report on Friday, September 13th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, Moderna currently has a consensus rating of Hold and a consensus price target of $100.44.

Moderna Trading Down 2.6 %

NASDAQ MRNA opened at $68.02 on Monday. The company has a quick ratio of 3.92, a current ratio of 4.09 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $26.07 billion, a P/E ratio of -4.34 and a beta of 1.68. Moderna has a 52-week low of $62.55 and a 52-week high of $170.47. The firm has a 50-day moving average price of $91.19 and a 200 day moving average price of $110.97.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.47) by $0.14. The business had revenue of $241.00 million during the quarter, compared to the consensus estimate of $128.41 million. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The company’s revenue for the quarter was down 29.9% on a year-over-year basis. During the same period in the prior year, the business posted ($3.62) EPS. Equities research analysts expect that Moderna will post -9.52 EPS for the current year.

Insider Transactions at Moderna

In related news, CFO James M. Mock sold 689 shares of the company’s stock in a transaction that occurred on Monday, July 8th. The shares were sold at an average price of $118.24, for a total transaction of $81,467.36. Following the transaction, the chief financial officer now owns 7,269 shares of the company’s stock, valued at $859,486.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the completion of the sale, the chief financial officer now owns 8,600 shares of the company’s stock, valued at $682,754. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO James M. Mock sold 689 shares of the stock in a transaction dated Monday, July 8th. The stock was sold at an average price of $118.24, for a total value of $81,467.36. Following the transaction, the chief financial officer now owns 7,269 shares in the company, valued at $859,486.56. The disclosure for this sale can be found here. Insiders sold a total of 93,158 shares of company stock worth $11,167,312 over the last ninety days. 15.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Cedar Wealth Management LLC grew its holdings in Moderna by 45.0% in the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after purchasing an additional 90 shares during the period. Commerzbank Aktiengesellschaft FI boosted its holdings in shares of Moderna by 1.7% in the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 5,550 shares of the company’s stock valued at $660,000 after purchasing an additional 93 shares during the last quarter. CVA Family Office LLC grew its stake in shares of Moderna by 21.6% during the 2nd quarter. CVA Family Office LLC now owns 541 shares of the company’s stock valued at $64,000 after buying an additional 96 shares during the period. Claro Advisors LLC increased its holdings in shares of Moderna by 2.0% during the 2nd quarter. Claro Advisors LLC now owns 5,546 shares of the company’s stock worth $659,000 after buying an additional 108 shares during the last quarter. Finally, EverSource Wealth Advisors LLC raised its position in shares of Moderna by 32.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 475 shares of the company’s stock worth $47,000 after buying an additional 116 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.